Abstract: Compositions are disclosed herein that comprise a mixture of at least one Albizia extract and a Magnolia extract. In some embodiments, the composition comprises a mixture of at least one Albizia extract enriched for one or more macrocyclic alkaloids and at least one Magnolia extract enrich for one or more lignans.

Abstract: This invention relates to the use of at least one following compound having formula (I), as well as the salts thereof, the optical and geometric isomers thereof, and the solvates thereof, as deodorant agent for treating body odor, preferably underarm odor:

Abstract: The invention provides new methods of treating patients benefiting from increased blood levels of alpha-lipoic acid. Such patients may include those suffering from various physiological disorders such as diabetic neuropathy. A dissolvable tablet, not meant to be swallowed, comprising alpha-lipoic acid in a limited release matrix provides means of administering therapeutically beneficial concentrations of alpha-lipoic acid without the commonly associated oral burn. Due to its orally dissolvable nature, this rate limiting matrix can deliver approximately IV-equivalent plasma levels of thioctic acid.

Abstract: The invention provides a method and bacterial compositions for reducing or preventing an infection of a bodily tissue by a fungal microorganism by contacting the tissue with a composition comprising a purified Lactobacillus paracasei bacterium.

Abstract: The invention relates to an actuator (1; 1a; 1b) which can be moved from an initial position into a working position having at least one actuator element (2; 2a; 2b) whose dimensions can changed by an electrical signal, Appropriately, at least two restoring means (20, 30; 20a, 30a; 20b, 30b) acting on the actuator element (2; 2a; 2b) are provided for movement into the working position. With the at least two restoring means, a total restoring means characteristic curve, which is composed of portions of the individual, preferably preloaded restoring means as well as a portion of a variable stiffness of the actuator element, can be advantageously tailored.

Abstract: The present invention relates to a chewing gum for mucosal delivery of cannabinoids, the chewing gum includes water-soluble chewing gum ingredients and water-insoluble gum base, wherein the gum base has one or more natural resins in an amount of 10-40% by weight of the gum base, one or more elastomers in an amount of 3-30% by weight of the gum base, and one or more elastomer plasticizers in an amount of 8-50% by weight of the gum base, and wherein the chewing gum includes one or more high intensity sweeteners in an amount of 0.01 to 1% by weight of the chewing gum, and wherein the chewing gum has one or more cannabinoids.

Abstract: The invention relates to a pharmaceutical or nutraceutical composition comprising an alkalized organic substance selected from the group comprising proteins, carbohydrates, lipids, amino acids, vitamins, therapeutic agents and mixtures thereof. Such compositions are useful for treating a range of diseases and conditions. They also give rise to beneficial physiological effects such as, for example, increasing physical strength, muscle mass and endurance.

Abstract: The invention encompasses compositions and methods for effectively treating and/or preventing diabetes and/or obesity. This is accomplished by totally addressing the multiple mechanisms that lead to such conditions. The invention includes compositions comprising a combination of agents that effectively suppress, regulate or interfere with the various biochemical processes and mechanisms that lead to diabetes and obesity.

Abstract: The invention encompasses compositions and methods for effectively interfering, reducing and preventing conversion of vascular smooth muscle cells (VSMCs) and circulating stem cells to osteoblastic bone-like cells, thereby reducing and/or preventing vascular calcification (VC) or calcium mineral (hydroxyapatite) deposition in the vasculature. The severity and extent of calcification in the major arteries reflect atherosclerotic plaque burden and strongly predict cardiovascular morbidity and mortality.

Abstract: Compositions and methods, including therapeutic alkaline phosphatases that find use in the treatment or prevention of various neurodevelopmental diseases or disorders, are described.

Abstract: Described herein are unit oral dose compositions that reduce the severity of heartburn and/or the risk of the occurrence of heartburn in a human in need of taking ibuprofen for the OTC treatment of acute pain wherein the human is not experiencing heartburn prior to the oral administration of the unit oral dose composition comprising orally administering to the human of a unit oral dose composition comprising (i) ibuprofen at a dosage from about 50 mg to about 400 mg per unit oral dose composition and (ii) famotidine at a dosage from about 3 mg to about 20 mg per unit oral dose composition, wherein the dissolution rate of famotidine in the unit oral dose composition in said human at a specified time within 45 minutes of administration of said unit oral dose composition to said human is greater than the dissolution rate of ibuprofen in the unit oral dose composition in said human at the same specified time.

Abstract: The present disclosure relates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q; Jeavons syndrome; Myoclonic Absence Epilepsy; Neuronal ceroid lipofuscinoses (NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Abstract: Disclosed herein are compositions and methods for treating, reducing or preventing oxidative stress in a subject. The compositions can be chewable confectionaries comprising a chewable base, one or more unprocessed phytochemical ingredients, and a sweetener comprising allulose. The unprocessed phytochemical ingredients can include ground plant materials selected from cinnamon, nutmeg, allspice, or combinations thereof. The chewable confectionary can exhibit a polyphenolic content of at least 100 ?g gallic acid equivalents (GAE) or greater, per gram of the chewable confectionary and an antioxidant capacity of at least 3,200 ?M Trolox equivalents per gram of the chewable confectionary, as determined by the oxygen radical absorbance (ORAC) assay. Kits, methods of making and using the chewable confectionary are also disclosed.

Abstract: The innovations provides an antimicrobial and synergistic phytochemical composition, consisting of two active ingredients (FZ and YC). This innovation also consists of formulation processes and its applications to fungi, bacteria and/or virus-caused plant diseases such as citrus Huanglongbing, grape downy mildew, strawberry gray mold etc. This innovation combines two ingredients (FZ and YC) with different modes of action, dramatically improving plant inducible acquired resistance. Therefore, this composition dramatically enhances the control efficacy of plant diseases caused by fungi, bacteria or virus, expands the antimicrobial spectrum and promotes the plant growth.

Abstract: A simple, self-propelling particle system is disclosed that can deliver a cargo through flowing aqueous solutions. This disclosure provides a non-aqueous composition comprising: (i) particles formed of a carbonate salt and having an average diameter of about 100 ?m or less; and (ii) an acid in solid form. The particles may be associated with a cargo molecule or particle. In mouse models of severe hemorrhage, the propelled particles are able to deliver a procoagulant enzyme and halt bleeding.

Abstract: The present invention provides mouthwash or mouthrinse compositions comprising one or more structuring agents selected from: a colloidal gum, a cellulosic polymer, an acrylate polymer, or a clay or fine particulate, and an orally acceptable aqueous carrier. In some embodiments, the total concentration of the one or more structuring agents is less than 5%, by weight, of the composition.

Abstract: The invention relates to a dental composition for use as a dental retraction material comprising filler(s), paste forming liquid(s) and guanidinyl-containing polymer(s). The dental composition is typically stored in a capsule with a thin nozzle enabling the delivery of the material in the sulcus of a tooth.

Abstract: This document provides methods and materials for treating lung conditions induced by inhalable insulin therapy. For example, compositions including a dried amnion tissue preparation and/or a dried stem cell preparation as well as methods for using such compositions to treat inhalable insulin induced lung conditions are provided.

Abstract: A chewable composition for teeth-whitening comprising a first region and a second region separated by a barrier layer; the first region comprising carbamide peroxide having water content of about 2% or less, a wetting agent (e.g., glycerin), an anhydrous chewing gum base having water content of about 1% or less, an anhydrous fruit acid, and one or more gum additives; and the second region comprising a chewable composition comprising a gum base, a source of bicarbonate ion, and one or more gum additives. A kit comprising separate chewable compositions corresponding to the first and second regions, and methods for whitening teeth using the chewable composition are also provided.

Abstract: Sealants for insulated glass units or solar panels are disclosed. The sealant comprises polyisobutylene and a polymer which is a copolymer obtained from the polymerisation of at least one ethylenically-unsaturated aliphatic hydrocarbon monomer and at least one monomer containing a maleic anhydride moiety. The copolymer comprises at least one amphiphilic polymer side chain. Processes for producing the sealants for insulated glass units or solar panels are also disclosed. Insulted glass units and solar panels comprising the sealant are also disclosed. Processes for producing the insulated glass units and solar panels comprising the sealant are also disclosed.

Abstract: A collection of therapies that are useful in a speech pathology setting, the common denominator of the therapies is that they each make use of chewing gum. Chewing gum administered to a patient can be used to treat swallowing disorders and oral motor impairments. In a major aspect of the invention, a series or kit of chewing gums of varying hardness can be used to treat mastication disorders. The gum exercise program will use the varying gum hardnesses as exercises for the muscles of the mouth, mastication, oral motor, sensory/stimulation, and swallowing therapeutic interventions. The instant therapies are more functional than existing dysphagia and oral motor interventions because they are similar to masticating real food by eliciting saliva production and taste buds from the gustatory response of the lemon and sour flavors. In addition, for sensory/stimulation exercises, the varying degrees of gum hardness, along with the lemon and other flavors, provide sensory feedback.

Abstract: Tetrahydroberberine (THB), isolated from the Chinese herb “Corydalis ambigua”, exhibits a variety of pharmacological effects, although mechanisms of action are unclear or entirely unknown. Described herein are novel methods of using tetrahydroberberine (THB), THB analogs or derivatives, tetrahydroprotoberberines (THPB). Tetrahydroberberine (THB) and analogs such as l-stepholidine (l-SPD) potently block functional KATP channels natively expressed on midbrain dopamine neurons. Further, THB also blocks pancreatic ?-cell KATP channels, and can be developed to a novel drugs for treating disease and/or conditions such as diabetes and Parkinson's disease.

Abstract: The present invention relates to solid forms of a substituted benzoxaborole compound, specifically crystalline forms of a compound of formula I, compositions comprising crystalline forms of the compound of formula (I), and methods of their use.

Abstract: A nutritional supplement composition is provided including an extract derived from common white kidney beans (Phaseolus vulgaris), Capsicum extract of the fruit of the Capsicum frutescens strain and Cinnamon extract of the bark of the Cinnamonium cassia strain. The nutritional supplement is in the form of a compound known as CLARIGEST™.

Abstract: The present invention is in the field of delivering an active substance to the oral cavity and relates to mucoadhesive active composition and corresponding mucoadhesive dosage form, which can deliver an active substance within the oral cavity, especially an orodispersible tablet for delivering probiotic substance. The present invention also relates to a method of producing the said composition and a method of processing the composition into a mucoadhesive dosage form, especially an orodispersible tablet. The present invention moreover relates to a system and a method for testing the mucoadhesion of a dosage form.

Abstract: This invention provides a method of using extract of Cistanche tubulosa. The extract was used to prevent, slow down, or treat an eye disease caused by oxidative stress. The method includes administrating to a subject in need a therapeutically effective amount of the extract of Cistanche tubulosa to prevent, slow down, or treat an eye disease caused by oxidative stress.

Abstract: The present disclosure is directed towards a paper product which can remain intact prior to and during usage and can self-disintegrate over time. Such a paper product can occupy less space in a user's waste bin following usage when compared with a similar paper product that does not self-disintegrate. Such a paper product can be treated with a topical binder that includes a sublimable material. The sublimable material can sublime away from the paper product over time thereby reducing the ability of the fibers of the paper product to remain bonded together.

Abstract: A medical chewing gum including gum base polymers and one or more cannabinoids as an active pharmaceutical ingredient, the gum base polymers including polyvinyl acetate and vinyl laurate-vinyl acetate copolymer in an amount of more than 90% by weight of the gum base polymers, wherein the gum base polymers include 20-95% by weight of polyvinyl acetate and 5-80% by weight of vinyl laurate-vinyl acetate copolymer.

Abstract: The present invention relates to a novel bacterial strain, L. plantarum GOS 42 (DSM 32131), isolated preparations and compositions thereof; and their use in medicine, especially in the treatment and/or prevention of inflammation.

Abstract: Oral compositions provide delivery of cannabinoids to a subject. The oral compare chewable, fast- or slow-dissolving once placed in the mouth of a subject.

Abstract: In some examples, the disclosure relates to a method including applying biomimetic mineralization process to an enamel defect of a tooth, wherein the applied biomimetic mineralization process remineralizes the tooth in the enamel defect. For example, applying a biomimetic mineralization process may include applying a polymer stabilized biomimetic mineralization composition in the area of the enamel defect and matrices, wherein the biomimetic mineralization composition infiltrates into a porosity of the enamel defect and crystalizes to remineralize the enamel defect. An example polymer stabilized biomimetic mineralization composition includes calcium, phosphate, and a polyanionic additive.

Abstract: An oral care formulation and method for removing tartar and plaque from the teeth, gums, and oral cavity is disclosed. The oral care formulation can take the form of a toothpaste, gel, wash, rinse, soak, spray, chewing gum, dental floss, or other suitable delivery system, containing a therapeutically effective amount of dimethyl isosorbide (DMI) (or equivalent or analog thereof) and chlorine dioxide (ClO2) for removal of tartar and plaque.

Abstract: Pharmaceutical compositions and methods of treatment or prevention of diseases and conditions associated with or characterized by at least one of xerostomia and periodontal disease by modulation of the nitric oxide synthase pathway are provided, as are animal models and drug screening methods. Such modulation may be achieved by the administration of tetrahydrobiopterin (BH4) or its prodrugs and/or salts. Treating and preventing xerostomia can have the downstream effect of also preventing periodontitis, dental caries, parotid gland enlargement, inflammation and fissuring of the lips (chelitis), inflammation or ulcers of the tongue and buccal mucosa, oral candidiasis, salivary gland infection (sialadenitis), halitosis, and cracking and fissuring of oral mucosa.

Abstract: In one aspect, a method of treating smokeless tobacco addiction comprising administering to an individual in need thereof a pharmaceutical composition comprising nicotine, a therapeutically effective amount of cannabidiol, and a pharmaceutically acceptable vehicle therefor. In some aspects, the composition is administered transmucosally, such as in an oral dosage form or nasal spray. In other aspects, the composition is administered transdermally. In another aspect, a chewable gum contains nicotine in at least a base portion and cannabidiol in at least an outer portion thereof.

Abstract: An oral care formulation and method for removing tartar and plaque from the teeth, gums, and oral cavity is disclosed. The oral care formulation can take the form of a toothpaste, gel, wash, rinse, soak, spray, chewing gum, dental floss, or other suitable delivery system, containing a therapeutically effective amount of dimethyl isosorbide (DMI) (or equivalent or analog thereof) and chlorine dioxide (ClO2) for removal of tartar and plaque.

Abstract: The present disclosure provides novel compounds that are steviol derivatives. The compounds generally can be characterized by a structure according to Formula I: wherein R1, A1, L1, and G1 are described herein. Also provided are sweetener compositions comprising the compound described herein either as a sweetener or a sweetener enhancer. Additionally, the compound or the sweetener composition can be included in a product such as a beverage product or a food product, which can reduce the amount of sweetener in the product required to achieve the same sweetness level in an otherwise identical product not including the compound or the sweetener composition.

Abstract: Stevia compositions are prepared from steviol glycosides of Stevia rebaudiana Bertoni. The compositions are able to provide a superior taste profile and can be used as sweetness enhancers, flavor enhancers and sweeteners in foods, beverages, cosmetics and pharmaceuticals.

Abstract: The present invention relates to a method for the preparation of a water-soluble extract based on a vegetable biomass of the Melissa officinalis family, which extract is used as a sulphite substitute in the aforesaid winemaking process, which method comprises one or more of the following steps: a) harvesting the herb, b) drying the herb obtained in step a), c) extracting the dried herb obtained in step b), wherein the aforesaid extraction step c) comprises at least two sub steps, a first sub step comprising a first extraction step with water, wherein the aqueous phase thus obtained functions as the starting material for the second sub step comprising an extraction step with an organic solvent, wherein the aqueous phase is acidified before the second extraction step.

Abstract: An oral care composition including an orally acceptable vehicle is disclosed. The orally acceptable vehicle includes a source of hydrogen peroxide, an acyl donor, and an enzyme that catalyzes the generation of peracetic acid between the source of hydrogen peroxide and the acyl donor.

Abstract: Stevia compositions are prepared from steviol glycosides of Stevia rebaudiana Bertoni. The compositions are able to provide a superior taste profile and can be used as sweetness enhancers, flavor enhancers and sweeteners in foods, beverages, cosmetics and pharmaceuticals.

Abstract: A pharmaceutical composition for treating non-alcoholic fatty liver diseases. The pharmaceutical composition is prepared from 8.75-60 parts by weight of silybin, 15-65 parts by weight of phospholipid, 25-150 parts by weight of a Pu'er tea extract, and 10.425-60 parts by weight of L-carnitine.

Abstract: The present invention relates to calcium carbonate particles, a powder mixture including such particles and a tooth cleaning method wherein the particles or powder mixture are used.

Abstract: An oral care composition comprising 20% to 75% of water by weight of the composition; 25% to 60% of a calcium-containing abrasive by weight of the composition; 0.001% to 5% of a flavorant by weight of the composition; and a rheology profile characterized by at least one of the following parameters: 10*K (Pa·s) value from 100 to 3,000; (?10000*)n (rate index) value from ?5000 to ?1300; 10*Yield Stress value from 100 to 3,500; Average G? value from 100 to 2000; or Average G? value 100 to 1000.

Abstract: The present invention relates to an oral care composition with a high water content which has improved robustness towards microbial challenge. The oral care composition includes compositions comprising from 0.125 wt % to 0.75 wt % of a water soluble source of stannous ions, wherein the composition comprises at least 50 wt % water and wherein the source of stannous ions is selected from the group consisting of stannous chloride, stannous pyrophosphate, stannous formate, stannous acetate, stannous gluconate, stannous lactate, stannous tartrate, stannous oxalate, stannous malonate, stannous citrate, stannous ethylene glyoxide, and mixtures thereof.

Abstract: A napkin band, the napkin band including: a generally rectangular portion; a sealed pocket located generally along the length of the rectangular portion; a length of dental floss located inside the pocket.

Abstract: A oral care composition comprising 20% to 75% of water by weight of the composition; 25% to 60% of a calcium-containing abrasive by weight of the composition; 0.1% to 15%, of a polyethylene glycol (PEG) by weight of the composition; and 0.001% to 5% of a flavorant composition by weight of the oral care composition.

Abstract: Compositions comprise an amount of cinnamaldehyde that is orally tolerable, thus avoiding an unpleasant mouth feeling, and also tolerable in the gastrointestinal tract. The amount of cinnamaldehyde is supplemented by zinc, and the combination is effective to increase at least one of energy expenditure, sympathetic nervous system activity, or fat oxidation, relative to a composition lacking cinnamaldehyde and zinc but otherwise identical. The composition comprising the combination of cinnamaldehyde and zinc can be used in a method to support weight managementor promote weight loss, a method for preventing obesity or overweight, and a method for treating obesity or overweight. In an embodiment, the composition comprising cinnamaldehydeis administered to a human. The composition comprising cinnamaldehyde may be a medicament, a food product or a supplement. The composition can improve one or more of insulin sensitivity, glucose tolerance, cognitive performance, cognition, mood or memory.

Abstract: A system and method which enables application of a material to teeth (and gums), which material remains in contact with, and adheres to, said teeth and gums for a period long enough to neutralize acids in dental plaque biofilm, inhibit plaque from adhering to teeth and gums, encourage removal of dental plaque, and form a barrier between the teeth and gums and the oral environment.

Abstract: Stevia compositions are prepared from steviol glycosides of Stevia rebaudiana Bertoni. The compositions are able to provide a superior taste profile and can be used as sweetness enhancers, flavor enhancers and sweeteners in foods, beverages, cosmetics and pharmaceuticals.

Abstract: The present invention relates to pharmaceutical compositions comprising a phosphonic acid compound, such as a natural product. Such compounds can include, such as an antibiotic or compound with other activity, derived from an Actinobacteria strain having a gene encoding pepM (phosphoenolpyruvate phosphomutase) or a pepM-dependent biosynthetic pathway. The present invention also relates to methods for treating or preventing or reducing the risk of a bacterial infection by administering a therapeutically effective or prophylactically effective amount of a phosphonic acid antibiotic, or a pharmaceutical composition containing such an antibiotic, to a patient or subject in need thereof. The present invention further relates to methods for isolating, purfying, and identifying such phosphonic acid compounds from Actinobacteria strains.